While typical cases may not need further testing, ultrasonography and electrodiagnostic studies are used for atypical cases to confirm the diagnosis and exclude other conditions. These studies are ...

Oral edaravone was approved in 2022 based on bioequivalence and long-term safety studies comparing it with the IV edaravone ...

A first-in-class anti-CD19 B-cell depleting agent was safe and demonstrated superior efficacy vs placebo in patients with ...

3). Hypesthesia was present about the lateral aspect of the shoulder. Electrodiagnostic studies indicated a reaction of degeneration involving the deltoid muscle, confirming the diagnosis of a ...

Weiss highlighted a 2012 Cochrane Library review that examined research and found the drug is “reasonably safe” and prolongs ...

Delandistrogene moxeparvovec (Elevidys), a gene therapy approved to treat Duchenne muscular dystrophy, missed its primary ...

SAVANNAH, Ga. -- One year after starting efgartigimod (Vyvgart) treatment, most generalized myasthenia gravis (gMG) patients ...

Tuesday announced positive topline data from the Phase 3 MINT study evaluating Uplizna for the treatment of adults ...

Johnson & Johnson (NYSE: JNJ) today announced positive results from the Phase 2/3 Vibrance-MG study of nipocalimab in anti-AChRa positive adolescents (aged 12 – 17 years) living with generalized ...

Amgen (NASDAQ:AMGN) today announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the ...

UCB will contribute 14 presentations, including an oral presentation, selected to feature across the AANEM and MGFA meeting, emphasizing UCB's leadership in neuromuscular researchPresentations ...